Views & Analysis ESMO review: advances in immunotherapy, EMA dialogue and pa... QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
ESMO2016 Cancer Market Commentary: Keytruda’s triumph not the last wo... Despite Keytruda's overwhelming victory, it's not over yet in NSCLC
News 23andMe stock sell-off adds to its woes Shares in genetic testing company 23andMe continue to slide after prominent investors announce plans to sell their stakes
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends